Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2

European Journal of Medicinal Chemistry

Volumn 67, Issue , 2013, Pages 115-126

  Juvale, Kapil ^a   Stefan, Katja ^a   Wiese, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Benzoflavones; Breast cancer resistance protein (BCRP); Flavonoids; MRP1; Multidrug resistance (MDR); P gp

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZOFLAVONE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CALCEIN; FLAVONE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MDCK CELL; MULTIDRUG RESISTANCE;

BENZOFLAVONES; BREAST CANCER RESISTANCE PROTEIN (BCRP); FLAVONOIDS; MRP1; MULTIDRUG RESISTANCE (MDR); P-GP;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOFLAVONES; CELLS, CULTURED; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONES; HUMANS; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84882504506     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.06.035     Document Type: Article

References (35)

1. A.T. Fojo, K. Ueda, D.J. Slamon, D.G. Poplack, M.M. Gottesman, I. Pastan, Expression of a multidrug-resistance gene in human tumors and tissues, Proc. Natl. Acad. Sci. U S A 84 (1987) 265-269. (Pubitemid 17013615)
2. W.S. Dalton, T.M. Grogan, P.S. Meltzer, R.J. Scheper, B.G. Durie, C.W. Taylor, T.P. Miller, S.E. Salmon, Drug-resistance in multiple myeloma and non-Hodgkin' s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy, J. Clin. Oncol. 7 (1989) 415-424. (Pubitemid 19098134)
3. L.M. Chan, S. Lowes, B.H. Hirst, The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability, Eur. J. Pharm. Sci. 21 (2004) 25-51. (Pubitemid 38050202)
4. P. Krishnamurthy, J.D. Schuetz, Role of ABCG2/BCRP in biology and medicine, Annu. Rev. Pharmacol. Toxicol. 46 (2006) 381-410. (Pubitemid 43271195)
5. O. Polgar, R.W. Robey, S.E. Bates, ABCG2: structure, function and role in drug response, Expert Opin. Drug Metab. Toxicol. 4 (2008) 1-15.
6. G. Schmitz, W.E. Kaminski, ABC transporters and cholesterol metabolism, Front Biosci. 6 (2001) D505-D514.
7. S. Velamakanni, S.L. Wei, T. Janvilisri, H.W. van Veen, ABCG transporters: structure, substrate specificities and physiological roles: a brief overview, J. Bioenerg. Biomembr. 39 (2007) 465-471.
8. H.C. Cooray, C.G. Blackmore, L. Maskell, M.A. Barrand, Localisation of breast cancer resistance protein in microvessel endothelium of human brain, Neuroreport 13 (2002) 2059-2063. (Pubitemid 36005925)
9. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, A.H. Schinkel, M.J. van De Vijver, R.J. Scheper, J.H. Schellens, Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues, Cancer Res. 61 (2001) 3458-3464. (Pubitemid 32695041)
10. F. Staud, P. Pavek, Breast cancer resistance protein (BCRP/ABCG2), Int. J. Biochem. Cell Biol. 37 (2005) 720-725. (Pubitemid 40202994)
11. T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, D.D. Ross, K. Miyake, J.H. Resau, S.E. Bates, The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2), J. Cell Sci. 113 (Pt 11) (2000) 2011-2021. (Pubitemid 30386505)
12. R.W. Robey, W.Y. Medina-Perez, K. Nishiyama, T. Lahusen, K. Miyake, T. Litman, A.M. Senderowicz, D.D. Ross, S.E. Bates, Overexpression of the ATPbinding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridolresistant human breast cancer cells, Clin. Cancer Res. 7 (2001) 145-152. (Pubitemid 32110217)
13. S.K. Rabindran, H. He, M. Singh, E. Brown, K.I. Collins, T. Annable, L.M. Greenberger, Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C, Cancer Res. 58 (1998) 5850-5858. (Pubitemid 29006428)
14. S. Zhang, X. Yang, M.E. Morris, Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport, Pharm. Res. 21 (2004) 1263-1273. (Pubitemid 38954213)
15. S. Zhang, X. Yang, R.A. Coburn, M.E. Morris, Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein, Biochem. Pharmacol. 70 (2005) 627-639. (Pubitemid 40978553)
16. A. Pick, H. Muller, R. Mayer, B. Haenisch, I.K. Pajeva, M. Weigt, H. Bonisch, C.E. Muller, M. Wiese, Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP), Bioorg. Med. Chem. 19 (2011) 2090-2102.
17. J. Yuan, I.L. Wong, T. Jiang, S.W. Wang, T. Liu, B.J. Wen, L.M. Chow, B. Wan Sheng, Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells, Eur. J. Med. Chem. 54 (2012) 413-422.
18. R. Clark, I.D. Kerr, R. Callaghan, Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter, Br. J. Pharmacol. 149 (2006) 506-515. (Pubitemid 44658511)
19. G. Valdameri, E. Genoux-Bastide, B. Peres, C. Gauthier, J. Guitton, R. Terreux, S.M.B. Winnischofer, M.E.M. Rocha, A. Boumendjel, A. Di Pietro, Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein, J. Med. Chem. 55 (2012) 966-970.
20. G. Valdameri, L. Pereira Rangel, C. Spatafora, J. Guitton, C. Gauthier, O. Arnaud, A. Ferreira-Pereira, P. Falson, S.M. Winnischofer, M.E. Rocha, C. Tringali, A.D. Pietro, Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein, ACS Chem. Biol. 7 (2012) 322-330.
21. Y. Han, M. Riwanto, M.L. Go, P.L. Ee, Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues, Eur. J. Pharm. Sci. 35 (2008) 30-41.
22. A. Boumendjel, A. McLeer-Florin, P. Champelovier, D. Allegro, D. Muhammad, F. Souard, M. Derouazi, V. Peyrot, B. Toussaint, J. Boutonnat, A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models, BMC Cancer 9 (2009) 242.
23. K. Juvale, V.F. Pape, M. Wiese, Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein, Bioorg. Med. Chem. 20 (2012) 346-355.
24. G. Valdameri, C. Gauthier, R. Terreux, R. Kachadourian, B.J. Day, S.M.B. Winnischofer, M.E.M. Rocha, V. Frachet, X. Ronot, A. Di Pietro, A. Boumendjel, Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity, J. Med. Chem. 55 (2012) 3193-3200.
25. S. Zhang, X. Wang, K. Sagawa, M.E. Morris, Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice, Drug Metab. Dispos. 33 (2005) 341-348. (Pubitemid 40279933)
26. J.D. Allen, A. van Loevezijn, J.M. Lakhai, M. van der Valk, O. van Tellingen, G. Reid, J.H. Schellens, G.J. Koomen, A.H. Schinkel, Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C, Mol. Cancer Ther. 1 (2002) 417-425.
27. M. Bennett, A.J. Burke, W.I. OSullivan, Aspects of the AlgareFlynneOyamada (AFO) reaction, Tetrahedron 52 (1996) 7163-7178.
28. K. Katayama, K. Masuyama, S. Yoshioka, H. Hasegawa, J. Mitsuhashi, Y. Sugimoto, Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship, Cancer Chemother. Pharmacol. 60 (2007) 789-797. (Pubitemid 47389385)
29. G. Casano, A. Dumetre, C. Pannecouque, S. Hutter, N. Azas, M. Robin, Anti-HIV and antiplasmodial activity of original flavonoid derivatives, Bioorg. Med. Chem. 18 (2010) 6012-6023.
30. G. Merino, J.W. Jonker, E. Wagenaar, A.E. van Herwaarden, A.H. Schinkel, The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin, Mol. Pharmacol. 67 (2005) 1758-1764. (Pubitemid 40594177)
31. H. Muller, W. Klinkhammer, C. Globisch, M.U. Kassack, I.K. Pajeva, M. Wiese, New functional assay of P-glycoprotein activity using Hoechst 33342, Bioorg. Med. Chem. 15 (2007) 7470-7479. (Pubitemid 47539132)
32. A. Pick, H. Muller, M. Wiese, Structureeactivity relationships of new inhibitors of breast cancer resistance protein (ABCG2), Bioorg. Med. Chem. 16 (2008) 8224-8236.
33. A. Pick, M. Wiese, Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway, Chem. Med. Chem. 7 (2012) 650-662.
34. H. Mueller, M.U. Kassack, M. Wiese, Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines, J. Biomol. Screen. 9 (2004) 506-515.
35. G. Valdameri, E. Genoux-Bastide, C. Gauthier, B. Peres, R. Terreux, S.M. Winnischofer, M.E. Rocha, A. Di Pietro, A. Boumendjel, 6-Halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein, Chem. Med. Chem. 7 (2012) 1177-1180.